ANI Pharmaceuticals (NASDAQ:ANIP) and Zynerba Pharmaceuticals (NASDAQ:ZYNE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares ANI Pharmaceuticals and Zynerba Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals $176.84 million 3.54 -$1.07 million $3.61 14.64
Zynerba Pharmaceuticals $10,000.00 8,656.33 -$32.01 million ($2.48) -1.98

ANI Pharmaceuticals has higher revenue and earnings than Zynerba Pharmaceuticals. Zynerba Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ANI Pharmaceuticals has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500. Comparatively, Zynerba Pharmaceuticals has a beta of 4.46, meaning that its share price is 346% more volatile than the S&P 500.

Insider and Institutional Ownership

63.3% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 16.5% of Zynerba Pharmaceuticals shares are held by institutional investors. 33.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 12.7% of Zynerba Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares ANI Pharmaceuticals and Zynerba Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 0.23% 28.39% 12.27%
Zynerba Pharmaceuticals N/A -74.82% -63.35%

Analyst Ratings

This is a breakdown of current ratings and target prices for ANI Pharmaceuticals and Zynerba Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 0 2 0 3.00
Zynerba Pharmaceuticals 0 1 5 0 2.83

ANI Pharmaceuticals currently has a consensus price target of $72.00, suggesting a potential upside of 36.26%. Zynerba Pharmaceuticals has a consensus price target of $20.10, suggesting a potential upside of 309.37%. Given Zynerba Pharmaceuticals’ higher possible upside, analysts plainly believe Zynerba Pharmaceuticals is more favorable than ANI Pharmaceuticals.


ANI Pharmaceuticals beats Zynerba Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with's FREE daily email newsletter.